Labopharm Reports Results for Third Quarter F...(llars except share and per share amo...),Health

and per share amounts) $ $ $ $

-------------------------------------------------------------------------

REVENUE

Product sales 2,818 1,097 10,359 4,044

Licensing 1,058 2,229 4,786 6,672

Research and development

collaborations 1,217 - 1,217 -

-------------------------------------------------------------------------

5,093 3,326 16,362 10,716

-------------------------------------------------------------------------

EXPENSES

Cost of goods sold

(excluding amortization) 1,012 691 6,716 2,267

Research and development

expenses, net 7,171 2,611 17,088 12,466

Selling, general and

administrative expenses 4,596 4,069 16,048 11,060

Financial expenses 434 644 1,474 2,056

Impairment loss on

long-term investment 874 - 874 -

Depreciation and

amortization 510 430 1,482 1,276

Interest income (810) (1,271) (2,707) (2,277)

Foreign exchange loss (gain) (107) (50) 280 (643)

-------------------------------------------------------------------------

13,680 7,124 41,255 26,205

-------------------------------------------------------------------------

LOSS BEFORE INCOME TAXES (8,587) (3,798) (24,893) (15,489)

Provision for income taxes

Current 508 598 1,710 1,282

Future (64) (35) (64) (71)

-
'/>"/>